AKR1B1 and diabetes mellitus: There are many targets underlying metabolic changes in diabetes which constitute possible therapeutics for this disease, namely the ability to modulate the activity of enzymes involved in the metabolism of carbohydrates (α-amylase and α-glucosidase) and glucose (aldose reductase) and the capacity to manage oxidative stress [11].